The three connective tissue disorders most commonly referenced together are lupus, scleroderma, and rheumatoid arthritis. All three are autoimmune diseases, meaning the immune system mistakenly attacks the body’s own connective tissue, the structural material that holds together joints, skin, blood vessels, and organs. While they share that underlying cause, each disorder targets different parts of the body and progresses in distinct ways.
Connective tissue disorders actually fall into two broad categories: autoimmune and hereditary. Hereditary types like Marfan syndrome and Ehlers-Danlos syndrome are caused by genetic mutations that weaken connective tissue from birth. But when people refer to “the three connective tissue disorders,” they’re typically talking about the autoimmune trio above, which are far more common and frequently diagnosed together in rheumatology.
Lupus
Lupus, formally called systemic lupus erythematosus (SLE), can cause inflammation in virtually any connective tissue in the body. That makes it one of the most unpredictable autoimmune diseases. It can affect your skin, joints, kidneys, heart, lungs, and brain, sometimes all at once, sometimes shifting from one system to another over time.
The most recognizable sign is a butterfly-shaped rash across the cheeks and nose, but many people with lupus never develop it. More common day-to-day symptoms include joint pain and swelling, fatigue, fevers, hair loss, and mouth sores. Kidney involvement is one of the most serious complications. When the immune system attacks kidney tissue, it can cause protein to leak into the urine and, without treatment, lead to permanent damage.
Lupus is diagnosed through a combination of blood tests and clinical symptoms. A positive antinuclear antibody (ANA) test is the starting point, but it’s not enough on its own since many healthy people test positive. Doctors look for a pattern of specific immune markers alongside symptoms like joint inflammation, blood cell abnormalities, and organ involvement. The disease is scored across multiple domains, and a threshold of clinical and immunological findings confirms the diagnosis.
Lupus disproportionately affects women, particularly women of color, and most commonly appears between ages 15 and 45. It’s a lifelong condition managed with medications that calm the immune system, and many people with lupus live full lives with periods of remission interrupted by flares.
Scleroderma
Scleroderma, also known as systemic sclerosis, causes the body to overproduce collagen, the protein that gives connective tissue its structure. The result is thickening and hardening of the skin and, in more severe forms, the internal organs. It comes in two main types that differ significantly in how far the disease spreads.
Limited scleroderma affects the skin of the fingers, hands, forearms, and sometimes the face. Internal organ damage is less common in this form, though some people develop digestive problems (especially heartburn), severe circulation issues in the fingers called Raynaud’s phenomenon, and in a small subset, dangerously high blood pressure in the lungs.
Diffuse scleroderma is more aggressive. Skin thickening extends across the arms, legs, trunk, and face, and it carries a higher risk of damage to the kidneys, lungs, heart, and digestive system. Life-threatening complications arise when the lungs or heart are severely affected. Acute spikes in blood pressure can also cause kidney damage. A study tracking patients over 15 years found that the five-year survival rate for systemic sclerosis overall is about 96%, dropping to 88% at ten years, with outcomes heavily influenced by whether the heart or lungs are involved.
Early symptoms often start with Raynaud’s phenomenon, where fingers turn white or blue in response to cold or stress, followed by skin tightening. There is no cure, but treatments can slow skin changes and manage organ complications.
Rheumatoid Arthritis
Rheumatoid arthritis (RA) primarily attacks the joints, but it’s a systemic connective tissue disease, not just a wear-and-tear problem like osteoarthritis. The immune system targets the synovium, the thin membrane lining the joints, causing it to become inflamed and dramatically thickened. In a healthy joint, this lining is one to three cells thick. In RA, it can swell to eight or ten cells thick, forming an aggressive tissue called pannus.
This pannus invades and erodes the cartilage and bone underneath. The inflamed synovium fills with immune cells, including the type that break down bone directly. New blood vessels grow into the inflamed tissue, feeding the process and accelerating destruction. Over time, this can lead to permanent joint deformity, particularly in the hands, wrists, and feet.
RA typically starts with morning stiffness lasting 30 minutes or more, along with swelling and tenderness in multiple joints, often symmetrically (both hands, both knees). Fatigue and low-grade fevers are common early on. The disease can also affect the eyes, lungs, and blood vessels, though joint destruction is the hallmark concern.
Early and aggressive treatment has transformed outcomes for RA over the past two decades. Medications that target the specific immune signals driving joint destruction can slow or even halt bone erosion if started early enough. Most people with RA today maintain good function and quality of life when the disease is caught and managed before significant joint damage occurs.
When These Disorders Overlap
These three diseases don’t always stay in their lanes. Some people develop features of two or all three simultaneously, a situation doctors call overlap syndrome. There’s also a distinct condition called mixed connective tissue disease (MCTD), which combines symptoms of lupus, scleroderma, and sometimes RA or inflammatory muscle disease into a single diagnosis.
MCTD has its own diagnostic hallmark: high levels of a specific antibody called anti-U1 RNP. To meet formal diagnostic criteria, a person needs elevated levels of this antibody plus at least three of five key features: swollen hands, joint inflammation, muscle inflammation, Raynaud’s phenomenon, and skin thickening on the fingers. MCTD is rarer than any of the three main disorders, but it illustrates how interconnected these conditions are at the immune system level.
Hereditary Connective Tissue Disorders
If you searched for three connective tissue disorders and expected a different list, you may have been thinking of the hereditary types. The three most commonly cited are Marfan syndrome, Ehlers-Danlos syndrome, and osteogenesis imperfecta. These aren’t caused by immune system malfunction. Instead, genetic mutations alter the proteins that build connective tissue.
Marfan syndrome affects elastin, the protein that gives tissues their stretch and recoil. People with Marfan syndrome often have long limbs and fingers, and the condition can cause serious cardiovascular problems because blood vessel walls lose their elasticity. Ehlers-Danlos syndrome involves defects in collagen production, leading to overly flexible joints and fragile, stretchy skin. Osteogenesis imperfecta, sometimes called brittle bone disease, results from defective type I collagen, the most abundant collagen in the body, causing bones that fracture easily.
These hereditary conditions are present from birth and managed very differently from the autoimmune trio, focusing on physical support, surgical correction, and preventing injury rather than suppressing the immune system.